Calliditas Therapeutics AB (NAS:CALT)
$ 40.0001 -0.1599 (-0.4%) Market Cap: 1.08 Bil Enterprise Value: 1.10 Bil PE Ratio: 0 PB Ratio: 104.30 GF Score: 35/100

Q1 2023 Calliditas Therapeutics AB Earnings Call Transcript

May 16, 2023 / 12:30PM GMT
Release Date Price: $21.17 (-16.98%)
Renee Aguiar;Lucander;publ;CEO
Calliditas Therapeutics AB

()-

Thank you very much, and welcome, everybody, to this Q1 2023 report. With me today, I have Fredrik Johansson, Chief Financial Officer; Richard Philipson, our Chief Medical Officer; and Andrew Udell, President of North America.

Next slide, please. I'd like to just draw your attention to the disclaimer page. It relates to any forward-looking statements, and I would like to refer you to the company's reports and other filings, including those which contain risk factors and other relevant information.

Next page, please. So some highlights for Q1. In February, we received conditional marketing authorization from the MHRA for Kinpeygo, which thus became the first-ever approved treatment for IgA nephropathy in the U.K. In March, we obviously had our main event for the quarter. We read out top line data from the global placebo-controlled randomized Phase III study known as NefIgArd, which met its primary endpoint of kidney function expressed as eGFR. The trial was very successful and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot